Enzymotec Lays Foundations for a New R&D Center in Israel
Earlier this year Enzymotec announced a global JV with AAK, Sweden for the production and marketing of InFat and a strategic alliance with Ranbaxy (India), a leading pharmaceutical company for the marketing of CardiaBeat in its territory.
08/08/07 Recently, Enzymotec has started construction at a 200,000 sqr foot site near its current location at Migdal HaEmeq, Israel. Enzymotec develops and produces novel ,lipid based, ingredients among which are: CardiaBeat, offering a broad health effect to reduce CVD risk: SharpPS, SharpPS SILVER and SharpPS GOLD for Improving cognitive performance and InFat for balanced nutrition for babies and toddlers.
This site will facilitate all of Enzymotec's current activities, including: management, R&D and local production, which are currently in Haifa Bay.
"During the past four years Enzymotec's activity had grown at a tremendous pace all over the world. Recent launches of our GPC and Krill oil have turned to be very successful and so our future growth can no longer be sustained by our current infrastructure. This plant will be the base of most of our products including: our SharpPS and CardiaBeat product lines", says Ariel Katz, Enzymotec CEO.
Earlier this year Enzymotec announced a global JV with AAK, Sweden for the production and marketing of InFat and a strategic alliance with Ranbaxy (India), a leading pharmaceutical company for the marketing of CardiaBeat in its territory.
